Guardant Health Q2 Revenue Jumps 44% on Screening Surge; 2031 Notes Become Convertible
GH has more than doubled off its 52-week low of $40.355.
Summary
Guardant Health's Q2 2026 revenue rose 44% to $335 million, fueled by a 257% jump in screening revenue. The 2031 convertible notes became convertible, and UnitedHealth Group will cover the Shield test starting August 1, 2026.
Key Events · Earnings and Guidance · GH
-
Revenue Surges 44%
Q2 2026 revenue reached $335 million, up 44% year-over-year, driven by a 257% increase in screening revenue to $52.9 million as Shield test volumes grew to approximately 66,000 tests.
-
Net Loss Widens on Investment
Net loss increased to $120.1 million from $99.9 million a year ago, reflecting heavy commercial infrastructure and marketing spending to support Shield and oncology growth.
-
2031 Notes Become Convertible
The $600 million 1.25% Convertible Senior Notes due 2031 became convertible at the holder's option from July 1, 2026, through September 30, 2026, after the stock price trigger was met. No conversions had been received as of July 24, 2026.
-
USPTO Rejects Key Patent Claims
On June 16, 2026, the USPTO issued a final office action rejecting all claims of the '631 patent as invalid, a significant positive development in the TwinStrand litigation where a $83.4 million jury verdict is under appeal.
Analysis · GH · Industrial Applications And Services
A 44% revenue jump to $335 million marked a standout quarter for Guardant Health, fueled by a 257% surge in screening revenue as Shield adoption accelerates. The net loss widened to $120 million, reflecting heavy investment in commercial expansion. Starting July 1, 2026, the 2031 convertible notes became convertible at the holder's option, introducing potential dilution overhang. On the legal front, the USPTO rejected all claims of the '631 patent—a positive development in the TwinStrand litigation—while UnitedHealth Group's decision to cover Shield starting August 1, 2026, represents a major commercial milestone.
At the time of this filing, GH was trading at $167.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $20.2B. The 52-week trading range was $40.36 to $174.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.